drugset / Trial / NCT03742973
A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA
RandomizedParallel-groupDouble-blindTreatment
Summary
This study evaluates the safety and efficacy of baricitinib in participants with primary biliary cholangitis (PBC) who do not respond or are unable to take ursodeoxycholic acid (UDCA).
Timeline
- Start
- 2019-03-28
- Primary completion
- 2019-09-26
- Completion
- 2019-09-26
Outcome
Outcome not reported
Stopped (Enrollment): “Study was terminated due to enrollment futility.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | 2 mg | Oral |
| Subject | Baricitinib | Small molecule | 4 mg | Oral |